Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Overview

USA - NASDAQ:STTK - US82024L1035 - Common Stock

2.28 USD
+0.05 (+2.24%)
Last: 9/19/2025, 8:00:00 PM
2.31 USD
+0.03 (+1.32%)
After Hours: 9/19/2025, 8:00:00 PM

STTK Key Statistics, Chart & Performance

Key Statistics
52 Week High3.95
52 Week Low0.69
Market Cap109.21M
Shares47.90M
Float34.41M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.21
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12/bmo
IPO10-09 2020-10-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


STTK short term performance overview.The bars show the price performance of STTK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

STTK long term performance overview.The bars show the price performance of STTK in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of STTK is 2.28 USD. In the past month the price increased by 154.83%. In the past year, price decreased by -39.04%.

SHATTUCK LABS INC / STTK Daily stock chart

STTK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.01 393.01B
AMGN AMGEN INC 13.09 153.65B
GILD GILEAD SCIENCES INC 14.74 141.56B
VRTX VERTEX PHARMACEUTICALS INC 22.62 98.23B
REGN REGENERON PHARMACEUTICALS 12.97 62.75B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.45B
ARGX ARGENX SE - ADR 79.48 45.09B
ONC BEONE MEDICINES LTD-ADR 5.84 39.75B
INSM INSMED INC N/A 30.60B
NTRA NATERA INC N/A 24.86B
BNTX BIONTECH SE-ADR N/A 23.13B
BIIB BIOGEN INC 8.9 20.89B

About STTK

Company Profile

STTK logo image Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Company Info

SHATTUCK LABS INC

500 W. 5Th Street, Suite 100

Austin TEXAS 78703 US

CEO: Taylor Schreiber

Employees: 44

STTK Company Website

STTK Investor Relations

Phone: 15129004690

SHATTUCK LABS INC / STTK FAQ

What is the stock price of SHATTUCK LABS INC today?

The current stock price of STTK is 2.28 USD. The price increased by 2.24% in the last trading session.


What is the ticker symbol for SHATTUCK LABS INC stock?

The exchange symbol of SHATTUCK LABS INC is STTK and it is listed on the Nasdaq exchange.


On which exchange is STTK stock listed?

STTK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SHATTUCK LABS INC stock?

12 analysts have analysed STTK and the average price target is 2.35 USD. This implies a price increase of 3.19% is expected in the next year compared to the current price of 2.28. Check the SHATTUCK LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SHATTUCK LABS INC worth?

SHATTUCK LABS INC (STTK) has a market capitalization of 109.21M USD. This makes STTK a Micro Cap stock.


How many employees does SHATTUCK LABS INC have?

SHATTUCK LABS INC (STTK) currently has 44 employees.


Is SHATTUCK LABS INC (STTK) expected to grow?

The Revenue of SHATTUCK LABS INC (STTK) is expected to decline by -100% in the next year. Check the estimates tab for more information on the STTK EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SHATTUCK LABS INC (STTK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SHATTUCK LABS INC (STTK) stock pay dividends?

STTK does not pay a dividend.


When does SHATTUCK LABS INC (STTK) report earnings?

SHATTUCK LABS INC (STTK) will report earnings on 2025-11-12, before the market open.


What is the Price/Earnings (PE) ratio of SHATTUCK LABS INC (STTK)?

SHATTUCK LABS INC (STTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).


What is the Short Interest ratio of SHATTUCK LABS INC (STTK) stock?

The outstanding short interest for SHATTUCK LABS INC (STTK) is 2.79% of its float. Check the ownership tab for more information on the STTK short interest.


STTK Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is one of the better performing stocks in the market, outperforming 90.4% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

STTK Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to STTK. While STTK has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

STTK Financial Highlights

Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 34.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -95.56%
ROE -107.88%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%42.86%
Sales Q2Q%-100%
EPS 1Y (TTM)34.59%
Revenue 1Y (TTM)-27.4%

STTK Forecast & Estimates

12 analysts have analysed STTK and the average price target is 2.35 USD. This implies a price increase of 3.19% is expected in the next year compared to the current price of 2.28.

For the next year, analysts expect an EPS growth of 43.36% and a revenue growth -100% for STTK


Analysts
Analysts78.33
Price Target2.35 (3.07%)
EPS Next Y43.36%
Revenue Next Year-100%

STTK Ownership

Ownership
Inst Owners55.29%
Ins Owners2.24%
Short Float %2.79%
Short Ratio0.35